GLP-1 Weight Loss Reshapes the Face — Here's How to Fix It

GLP-1 receptor agonists have rapidly become some of the most prescribed drugs in the world, delivering substantial weight loss for millions of patients. But as clinical experience grows, so does recognition of an unintended consequence: a pattern of facial aging informally called 'Ozempic face,' characterized by hollowing, skin laxity, and loss of youthful contour.

This narrative review, published in Dermatologic Surgery, takes a systematic anatomical lens to understand exactly why the face changes so dramatically after GLP-1-induced weight loss. The authors — plastic surgeons and dermatologists from Germany, Canada, and Spain — analyze how rapid fat loss cascades through multiple structural layers of the face.

Key findings point to deflation of superficial fat compartments as a primary driver, particularly in the midface. This flattens contours and deepens transition lines, creating an older, more hollowed appearance. Compounding this, deep structural support is diminished, skeletal resorption occurs, and skin loses elasticity faster than it can remodel — especially with rapid weight loss.

Based on these mechanisms, the authors advocate a two-pronged aesthetic treatment strategy. First, early biostimulation using collagen-stimulating agents (such as poly-L-lactic acid or calcium hydroxylapatite) to improve skin quality and dermal thickness before volume loss becomes severe. Second, targeted hyaluronic acid filler placement to restore structural support and correct compartment-specific deflation.

While compelling and clinically relevant, this review is based on a narrative synthesis rather than controlled clinical trials, and lacks patient outcome data specific to GLP-1 users. As GLP-1 prescriptions continue to soar, this anatomical framework offers dermatologists and plastic surgeons a practical, evidence-informed approach to managing one of the drug class's most visible side effects.